anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To assess the safety and effectiveness of tubed versus tubeless percutaneous nephrolithotomy (PCNL) after tract inspection and bipolar cauterization of the significant bleeders. Patients who were scheduled for PCNL were screened for enrollment in this prospective randomized controlled trial. The patients were randomly assigned to one of two groups; Group 1 received tubeless PCNL with endoscopic inspection of the access tract using bipolar cauterization of the significant bleeders only, while Group 2 had a nephrostomy tube was inserted without tract inspection. We excluded patients with multiple tracts, stone clearance failure, and significant collecting system perforation. We recorded blood loss, hemoglobin drop after 6 h, postoperative analgesia requirements, hospital stay, and the need for angioembolization. A total of 110 patients completed the study. There were no significant differences between the two groups in in terms of demographic characteristics. Likewise, there was no significant difference in the mean decrease in hemoglobin after 6 h and the frequency of blood transfusion. However, the incidence of hematuria within the first 6 h (p = 0.008), postoperative pain scale (p = 0.0001), the rate of analgesia requirement (p = 0.0001) and prolonged hospital stay (p = 0.0001) were significantly higher in Group 2. Only 9 cases of tract screened patients (16% of group 1) required cauterization. Tubeless PCNL with tract inspection and cauterization of bleeders can provide a safer tubeless PCNL with less postoperative pain, analgesia requirement, and same-day discharge.
This procedure will be performed either in a minor procedure room or the hand clinic as per surgeon's routine practice. Collagenase will be administered with or without local anesthesia. As this is a pragmatic study there may be more than one digit injected at a time just as surgery occurs on more than one digit at a time. A recently published study by Gaston et al confirmed that two concurrent injections of collagenase to 2 affected joints in the same hand are generally well tolerated and the frequency of most adverse events (AEs) is similar to those reported in studies that use single sequential injections.
FIELD: cosmetology and dermatology. SUBSTANCE: culture medium for cells contains ecdisteroid, ecdisteroid derivative or containing its vegetable and/or animal extract - agent or regulation of cells differentiation. Culture medium may be preferably used in method for mass cultivation of keratinocytes. The method provides for perfusion of nutrient medium and its sufficient quantity fro growth and differentiation even when biomass is in considerable quantities. The agent of regulation of cells differential makes it possible to improve quality of cosmetic and dermatological compositions. EFFECT: higher efficiency. 24 cl, 1 tbl, 12 ex
PURPOSE:A carcinostatic agent that contains mannose monophosphate derivative as active ingredient. CONSTITUTION:A carcinostatic agent is obtained by using a compound of the formula (R is saturated or unsaturated aliphatic group of 20-120 carbon atoms). The dose is 10mg-2g/kg/day in oral administration and 4mg-1g/kg/day in parenteral administration. The formulation for oral administration is tablets, granlues or powder (containing capsules) and may contain silicic anhydride, meta-silicic acid, magnesium aluminate as a diluent, arabic gum or gelatin as a binder, magnesium stearate or talc as a lubricant and potato starch as a disintegrator. As an injection preparation, is it used in the form of an oil solution, emulsion or aqueous solution. The compound of the formula is obtained by reaction of a compound of R-OPO3H2 or its alkali addition salt with guanosine- diphosphomannose in the presence of a divalent metal ion and crushed yeast.
This patent describes the use of ploycations that contain photosensitive groups to fabricate microcapsules. The microcapsular membrane is formed firstly by the coacervation reaction between the polyanions (e.g. alginate) and derivatives of polycations. In addition to the conventional charge interaction between the two different polyelectrolytes, the capsular membrane is strengthen by covalent bonding. For example, cinnamylidene groups of the polyvinylamine derivatives can crosslink with each other after light irradiation. Because visible light is used in this reaction, the cells entrapped in the microcapsules are not damaged by this treatment. The mechanical strength of the crosslinked capsular membrane is much stronger than that prepared by the conventional coacervation techniques. In addition, the cell proliferation rate remains unaffected. This techniques for microcapsule preparation has great potential in medical and bioindustrial applications.
Disclosed aspects relate to generating rationales for treatment options. A set of preference scores that indicates a first preference score for a first treatment option of a set of treatment options may be received. A rank-order that indicates a first ranking for the first treatment option may be received. The set of preference scores may be analyzed with respect to the rank-order to determine a relationship between the first preference score and the first ranking for the first treatment option. Based on the relationship between the first preference score and the first ranking, a set of rationale data for the first treatment option may be generated with respect to the first rank. Based on a user profile for a user, the set of rationale data may be configured for the user. The set of rationale data which is configured for the user may be provided.
Oral prasterone 200 mg / day reduced the risk of auto-immune flare, §§6.2, 14.1, and significantly reduced the risk of death, §§6.4, 14.2, in placebo-controlled, randomized, blinded clinical studies (GL94-01, GL95-01, GL95-02 and GLB96-01) in female patients with Systemic Lupus Erythematosus. Results observed in clinical trials may not, however, reflect the rates observed in practice. 

PRASTERA® does not cure, mitigate, treat or prevent the patient's underlying SLE. To the contrary, the patient will continue to have SLE. The patient therefore should continue to be monitored by a physician and should continue other therapy (e.g., prednisone, NSAID) as believed appropriate. 

Oral prasterone reduced the risk of auto-immune flare and death. See above. PRASTERA® may not, however, make the patient feel significantly different on a day-to-day basis. This does not mean PRASTERA® is not working; it may take at least six months of continuous therapy to achieve a statistically-significant reduction in risk of flare and death. §14.
The majority of people will suffer from low back pain at some point in their life with 15-25% of axial low back pain originating at the sacroiliac (SI) joint. This pain is thought to be due to inflammation of the SI joint capsule, ligaments or bone. Following conservative management strategies such as mobility work, core strengthening and physiotherapy, as well as pharmacologic management, an SI joint injection would be the next treatment modality. Corticosteroid injections are currently the standard of care for joint injections. The corticosteroid minimizes pain by interrupting the bodies inflammatory cascade primarily by inhibiting the phospholipase A2 enzyme. However, with repetitive use, steroids can cause cartilaginous damage of the joint. With chondrocyte dysfunction being a key part of early osteoarthritis, these injections may expedite the arthritic joint changes. Due to this damage, physicians try to spread out joint injections as far as possible to reduce this risk even if the patient begins to experience more severe joint pain.

One possible alternative to steroids is the use of ketorolac, an non-steroidal anti-inflammatory drug (NSAID). Ketorolac joint injections have been shown to have similar pain reducing effects to steroids when used for shoulder, knee, hip and carpometacarpal joint pain. They have also been used widely in the National Football League to treat musculoskeletal injuries and in the post-operative phase to reduce opioid usage to manage pain. NSAIDS provide analgesia by inhibiting the cyclooxygenase (COX) family of enzymes that are involved with formation of prostaglandins. These prostaglandins are inflammatory mediators that promote inflammation and activates nociceptive neurotransmitters. Although there are known side effects of NSAIDs including increasing propensity for GI bleeds, kidney and liver disease, joint injections may have less systemic side effects compared to their oral counterparts. Another benefit of Ketorolac is the fact it is significantly cheaper than steroids. With less chondrotoxic effects, perhaps Ketorolac injections could be administered more frequently, not allowing the patient to have increasing pain levels, at less cost to the health care system even with more frequent administration.
Colorectal cancers, inflammatory colon diseases, colorectal diseases for which medical treatment cannot be successful, diverticula, perforation, obstruction, etc. These conditions are among the conditions requiring colorectal surgical treatment. Colorectal cancer is the most common reason for colorectal surgery and causes illness and death all over the world. Conditions that cause pain in colorectal surgery: Painful drainage in perianal fistulas, hemorrhoidal diseases, perianal hernia, ulcerative colitis, surgical interventions, stoma and peristomal skin complications. In addition, patients experience serious pain when there is more than one source of pain due to the size of the incision area, cutting of skin and muscles, nerve damage, etc. When evaluated numerically, the pain experienced after surgery increases up to 8 out of 10, especially in the first 24 hours, and decreases below 4 after the 72nd hour. In cases where severe pain is not adequately controlled, patients do not want to move and the digestive system causes a decline in intestinal functions due to decreased blood flow. For effective pain management, pain should be questioned constantly, its location and spread, character (noiceptive, neuropathic, visceral), severity, duration (continuous, intermittent, paroxysmal), factors that increase or decrease, symptoms accompanying the pain, symptoms caused by the pain, previous treatments. The reasons that prevent the evaluation of the response and pain should be determined and patient-specific pain management should be planned.

In addition, strong opioids such as morphine and talinate, which are administered in high doses for pain treatment, cause the bowel functions to slow down and increase the rates of paralytic ileus, constipation and distension. In this context, the multimodal analgesia approach, in which more than one method is used, provides more effective pain control than a single analgesia approach and also reduces the complication rates in bowel functions.

It is a non-invasive and safe analgesic method in gastrointestinal surgery that acts through multiple mechanisms. In the nursing regulation published in 2011, independent, semi-dependent and dependent roles of nurses were defined. TENS should be applied in the postoperative period to provide effective analgesia, reduce the use of pharmacological analgesics, and improve the patients bowel functions in the early period. The mechanism of action of TENS on the body is explained by two types of mechanisms. Since nurses, who have a key role in pain management, do not have the authority to decide on the type and dose of analgesic medication to be administered, their role in pain management is limited, but nurses. If there is more than one source of pain due to the size of the incision area, cutting of skin and muscles, nerve damage, etc., patients experience serious pain and regression in bowel functions due to pain.
PURPOSE: The aim of the present systematic review is to collect all the available evidence regarding the clinical and radiological results of revision to reverse shoulder arthroplasty (RSA) of modular anatomic shoulder prostheses (TSA) using a convertible metal-backed glenoid (MBG).
METHODS: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Studies investigating revision of TSA to RSA utilizing a convertible MBG and reporting clinical and radiological outcomes were identified.
RESULTS: A total of five studies on the use of convertible modular glenoid component in the setting of TSA revision to RSA were finally included in the present systematic review. A total of 60 procedures were reported. Mean operative times was 65 min. Intraoperative complications included 3 cases of glenoid loosening. Only one case of dislocation was reported as postoperative complication. At mean follow-up of 32.3 months post-revision, no glenoid loosening was reported, VAS score decreased from 7.7 to 1.5, Constant Score increased from 24.8 to 57.6.
CONCLUSIONS: Revision to RSA after failed TSA using a convertible modular glenoid component was associated with a low rate of intraoperative and postoperative complications, low surgical time and led to good results in term of pain relieve and functional outcomes. Given the complexity and risk associated with revision of anatomic shoulder prosthesis having a convertible glenoid may help to simplify the procedure and improve clinical results.
The present invention discloses bone-setting medicine and a preparation method thereof. The bone-setting medicine comprises external medicine, namely analgesic bone-setting paste, and internal medicine, namely ostealgia relieving capsules and traumatic rheumatism medicine. The external medicine, namely the analgesic bone-setting paste, is prepared by compounding multiple traditional Chinese medicine of native copper, acanthopanax bark, ground beetle, pyrolusite, nutgall, calamitas urinae hominis, etc. according to a certain proportion. The internal medicine, namely the bone-setting capsules, is prepared by compounding ground beetle, native copper, dragon's blood, safflower, cucumber seed and pyrolusite. Bone-setting medicinal wine is prepared from multiple raw material medicine of epimedium herb, coix seed, achyranthes root, angelica, etc. according to a certain proportion. The bone-setting medicine has the characteristics of good effect on curing bone injuries of fractures, traumatic injuries, etc., short treatment course, high cure rate and obvious effect faster than that of the similar medicine after use. The bone-setting medicine is worth being popularized and applied.
Patients presenting to the Emergency Department for acute asthma exacerbation will receive standard care of up to three doses of albuterol and ipratropium bromide plus oral steroid medication. Those seven years of age and older who require further treatment will be screened for eligibility. Eligibility screening will comprise measurement of forced expiratory volume in one second (FEV1) with a bedside spirometer by a respiratory therapist. Children under the age of seven are generally unable to complete spirometry maneuvers and will thus be excluded. The Pediatric Asthma Severity Score (PASS) will also be noted by a respiratory therapist. Patients able to complete spirometry testing and with an FEV1 less than 70% of predicted (the definition of moderate asthma exacerbation) will be enrolled. Enrolled patients will be randomized to receive either Children's Medical Center standard care of 15 mg albuterol diluted in 22 ml of normal saline or the study intervention of 15 mg of albuterol diluted in 22 ml of magnesium sulfate solution. This solution will be prepared at the time of use by a pharmacist in the Emergency Department and will consist of 22 ml of a commercially available 40 mg/ml magnesium sulfate solution (880 mg). The nebulizer treatment will be given over approximately one hour via a large volume nebulizer at 25 ml/hr. Physicians, nurses, and respiratory therapists will be blinded to the diluent used. Vital signs will be noted at baseline. Heart rate, heart rhythm, respiratory rate, and pulse oximetry will be monitored continuously while blood pressure will be measured at baseline and every 15 minutes during study medication administration. The study physician, treating physician, and/or bedside nurse will monitor these values for any clinically significant changes. At the end of the 15 mg albuterol treatment FEV1 and PASS will again be noted. Any further treatments needed, as determined by the treating physician, will be given following Children's Medical Center standard of care. At the discretion of the treating physician intravenous magnesium sulfate may be used post study intervention. The dose used for study participants will be the Children's Medical Center standard dose of 75 mg/kg (max 3 g) minus 880 mg to avoid the risk of magnesium sulfate overdose. Further treatments and patient disposition will be observed by study personnel and noted. Bounce-back rates will be collected by review of enrolled patients' medical record.
FIELD: medicine. SUBSTANCE: method involves determining three black points by means of a finger through the rectum and fixing them in succession. Novocaine solution is injected into the center of a selected trigger point. Tissular response is determined with finger from the rectum side. After trigger point being relaxed, that is to be accompanied with vanishing pain, Novocaine solution injection is stopped. EFFECT: completely removed pains in the vertebral column.
To identify those who might benefit from weight reduction within a large population of obese individuals, Japan Society for the Study of Obesity (JASSO) advocated the concept of "obesity disease." Here we summarize the definition, criteria, and core concepts for the management of obesity disease based on JASSO's latest guideline. JASSO defines obesity as excessive fat storage in adipose tissue associated with a BMI of ≥25 kg/m2. The threshold BMI of obesity is low as compared to Western countries given that Japanese individuals tend to develop obesity-related health disorders at lower BMI. Obesity with a BMI of ≥35 kg/m2 is referred to as "high-degree obesity" as treatment strategies vary based on the degree of obesity. Obesity is diagnosed as "obesity disease" if accompanied by any of the 11 specific obesity-related health disorders that weight reduction can prevent or alleviate, or if it meets the criteria for visceral fat obesity with a visceral fat area of ≥100 cm2. The initial weight reduction goals for high-degree obesity disease range from 5% to 10% of their current body weight, depending on the associated health disorders. That for those with obesity disease who do not qualify as high-degree is 3% or more. If these initial goals are not achieved, intensifying dietary therapy or introducing drug therapy (or both) may be necessary. While surgical treatment is primarily indicated for high-degree obesity disease, it might be appropriate for cases of obesity disease with a BMI <35 kg/m2, depending on the accompanying health disorders. Enhancing the quality of life for individuals with obesity or obesity disease necessitates a broader societal approach, emphasizing the resolution of related stigma.
The present invention provides an online virtual laboratory manager that allows for electronic documentation and management of all aspects of the laboratory. The system receives data from one or more instruments in a laboratory and stores the data in a central library. The data is compared against compliance target values to determine if the one or more instruments are in compliance, and if the data is out of the compliance target values, notifying a laboratory manager. In notifying the laboratory manager, the laboratory manager is provided with corrective actions that are required, and thereafter, the system documents any data changes that occur. Additionally, the data from a plurality of laboratories is stored in the central laboratory to allow for peer review across laboratories. The system allows for monitoring the laboratory, identifying and fixing issues, and document all aspects for regulatory compliance, including allowing instant regulatory access to laboratory logs.
PURPOSE:To obtain the titled composition, by blending a benzimidazole based compound with a specific basic inorganic salt. CONSTITUTION:A stabilized pharmaceutical composition obtained by blending 1pts.wt. compound expressed by formula I (R<1> is H, alkyl, halogen, cyano, etc.; R<2> is H, alkyl, acyl, carboalkoxy, etc.; R<3> and R<5> are H, alkyl, alkoxy, etc.; R<4> is H, alkyl, alkoxy which may be fluorinated, etc.; m is 0-4) or a derivative thereof with 0.3-20pts.wt. basic inorganic salt of magnesium and/or calcium. This composition is a remedy for peptic ulcer having inhibition of gastric acid secretion as main action. The compound expressed by formula I can be obtained by a method for subjecting a compound expressed by formula II prepared by reacting a compound expressed by formula III with a compound expressed by formula IV (X is halogen) to oxidative reaction, etc. The dose thereof is 0.01-30mg/kg/day, preferably 0.1-3mg/kg/day expressed in terms of the compound expressed by formula I.
Patients in the control group receive usual care during their hospital stay and after discharge at the municipality training centre. Data are recorded at baseline and 6 and 12 weeks after discharge.
A response to the case report by Zhang et al. and supplement another case of giant peritoneal loose body discovered due to abdominal pain. A 68-year-old man was admitted to the hospital with abdominal pain. CT revealed an ovoid mass in the pelvis measuring approximately 11.5 × 8.6 × 7.4 cm. During laparotomy, yellowish-white mass was identified within the pelvis. Histological examination revealed that the mass was hyalinized fibrous connective tissue with focal calcification. We report an extremely rare and interesting case.
The intervention group will receive music listening at sleep time and will be invited to join a social network for 12 weeks. But their sleep quality , sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 3 mm.
The invention relates to lysozyme, specifically to a Mytilus edulis G-type lysozyme gene and a recombinant protein and application thereof. The G-type lysozyme gene is represented by a base sequence of SEQ ID No. 1 in a sequence table. A recombination expression product of the G-type lysozyme gene can be used for preparing an antibacterial agent, an aquatic product antistaling agent or an aquatic product feed additive. Mytilus edulis G-type lysozyme in the invention can be prepared through the following steps: extraction of total RNA from Mytilus edulis infected with pathogens, purification of mRNA, preparation of a cDNA template solution, screening of the G-type lysozyme gene, gene cloning, construction of recombinant plasmid, expression of a recombinant gene and purification of the recombinant protein, and an amino acid sequence of the G-type lysozyme is represented by SEQ ID No. 2 in the sequence table. The G-type lysozyme belongs to a novel Mytilus edulis lysozyme and has powerful inhibitory activity on a variety of marine-derived Gram positive and negative pathogenic microorganisms.
The present disclosure provides a  Bifidobacterium lactis  ( B. lactis ) strain XLTG11 and a use thereof. The strain belongs to  Bifidobacterium lactis . The  B. lactis  strain XLTG11 was deposited in the China General Microbiological Culture Collection Center (CGMCC) on Oct. 25, 2019, with a taxonomic name of  Bifidobacterium lactis  XLTG11 and an accession number of CGMCC No. 18738. The  B. lactis  strain XLTG11 provided by the present disclosure can regulate an inflammatory cytokine, improve an intestinal barrier function, and modulate an intestinal flora by inhibiting the activation of a TLR4/MYD88/NF-κB signaling pathway, thereby alleviating dextran sulfate sodium (DSS)-induced colitis. In addition, the  B. lactis  strain XLTG11 has an immune-enhancing effect on a cyclophosphamide (CTX)-induced mouse immunosuppression model.